Emergent BioSolutions Inc. (EBS) company profile
Close on Nov 17, 2026Market cap $287.64MP/E –Yield –
About Emergent BioSolutions
Pharmaceutical Preparations, SIC 2834
The company is a life sciences enterprise that develops and supplies medical solutions to address public health threats, including chemical, biological, and nuclear hazards, infectious diseases, and emergency health crises. Its operations comprise three primary segments: Commercial Products, Medical Countermeasures, and Services. The Commercial segment supplies opioid overdose treatments, notably NARCAN and KLOXXADO nasal sprays. The Medical Countermeasures segment provides vaccines and therapeutics against severe threats such as smallpox, anthrax, and botulism, featuring ACAM2000, BioThrax, and BAT. The Services segment delivers contract development and manufacturing capabilities for external clients. Its customers include the United States government, foreign governments, healthcare departments, law enforcement agencies, community organizations, pharmacies, and commercial biopharmaceutical companies.
The company operates four development and manufacturing facilities across the United States and Canada, located in Gaithersburg, Canton, Lansing, and Winnipeg. It delivers products globally, supplying medical countermeasures to international partners and distributing its botulism antitoxin to nineteen foreign countries. The provided text does not state the location of its headquarters.
Summary of the business section of Emergent BioSolutions's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Emergent BioSolutions Inc.
- Founded
- 1998
- Headquarters
- Gaithersburg, MD
- Address
- 300 Professional Dr 20879
- Phone
- (240) 631-3200
- Website
- emergentbiosolutions.com
- Employees
- 900, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Tysons, Virginia
Stock & identifiers
- Ticker
- EBS
- Exchange
- NYSE
- IPO date
- Nov 15, 2006
- Shares outstanding
- 51M, Jul 30, 2026
- Public float
- $342.70M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1367644
- CUSIP
- 29089Q105
- ISIN
- US29089Q1058
- FIGI
- BBG000GW06J7
- Share class FIGI
- BBG001SP1G40
- LEI
- 549300YW6TUOX8BE5103
- EIN
- 14-1902018
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Zsolt Harsanyi | Chairman, Director | 149,076 |
| Joseph C. Papa | President and CEO, Director | 493,153 |
| Paul Anthony Williams | SVP, Products Business | 156,098 |
| Stephanie Duatschek | EVP, CGO | 197,416 |
| Richard S. Lindahl | EVP, Chief Financial Officer | 374,083 |
| Coleen Glessner | EVP, Quality & Ethics, and CPL | 202,201 |
| William Hartzel | SVP, Bioservices | 185,558 |
| Jessica Perl | SVP, General Counsel, Corp Sec | 165,286 |
| Simon C. Lowry | SVP, R&D, CMO | 177,914 |
| Donald W. DeGolyer | Director | 111,921 |
| John D. Fowler Jr | Director | 30,350 |
| Marvin L. White | Director | 113,839 |
| Ronald Richard | Director | 123,761 |
| Keith Katkin | Director | 96,294 |
| Kathryn C. Zoon | Director | 80,998 |
| Neal Franklin Fowler | Director | 160,847 |
| Sujata Tyagi Dayal | Director | 101,543 |
| Louis W. Sullivan | Director | 139,098 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $5.32M | $9.36M | $1.81M | $14 | $171 |
| FY2024 Miller | $218.75K | $218.75K | $1.79M | $18 | $147 |
| FY2024 Papa | $5.86M | $19.53M | $1.79M | $18 | $147 |
| FY2023 Kramer | $5.10M | $393.08K | $1.81M | $4 | $146 |
| FY2023 Miller | $766.67K | $766.67K | $1.81M | $4 | $146 |
| FY2023 Mr.Kramer | $5.10M | $393.08K | $1.81M | $4 | $146 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Joseph Papa President, Chief Executive Officer and Director | $1.04M | $1.64M | $1.19M | $1.45M | $7.12K | $5.32M | -9% |
| Richard Lindahl Executive Vice President, Chief Financial Officer | $662.02K | $851.95K | $753.05K | $431.20K | $10.50K | $2.71M | +17% |
| Coleen Glessner Executive Vice President, Quality and Ethics and Compliance | $623.55K | $362.50K | $263.61K | $406.08K | $8.52K | $1.66M | -19% |
| Simon Lowry Chief Medical Officer and Head of Research and Development | $545.00K | $362.50K | $263.61K | $289.67K | $10.50K | $1.47M | – |
| Paul Williams Senior Vice President, Products Business | $495.02K | $362.50K | $263.61K | $262.61K | $7.43K | $1.39M | -17% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Nov 15, 2006
- Offer price
- $12.50
- Securities offered
- 5,000,000
- Gross proceeds
- $62.50M
- Exchange
- NYSE
- First trading day
- Nov 15, 2006
- First-day close
- $11.70-6.4%
- Lock-up ends (est.)
- May 14, 2007
“Our common stock has been authorized for listing on the New York Stock Exchange under the symbol “EBS.” Per share Total Initial public offering price $ 12.500 $ 62,500,000 Underwriting discounts and commissions $ 0.875 $ 4,375,000 Proceeds to Emergent, before expenses $ 11.625 $ 58,125,000 The underwriters have an option for a period of 30 days to purchase up to 480,000 additional shares of common stock from the sell”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 900 employees globally.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?